Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model

Prathibha Shetty; Anirban M. Thakur; Chandra Viswanathan

doi:10.1002/cbin.10029

journal article Jan 21, 2013

Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model

Prathibha Shetty Anirban M. Thakur Chandra Viswanathan

Cell Biology International Vol. 37 No. 2 pp. 167-180 · Wiley

View at Publisher Save 10.1002/cbin.10029

Abstract

AbstractMesenchymal stem cells (MSCs) could be an alternative to foetal cells in the treatment of several neurodegenerative diseases, especially Parkinson's disease (PD). We have previously demonstrated the functional efficacy of the undifferentiated bone marrow MSCs (BMMSCs) cultured in a xenofree conditions in PD animal models. We now demonstrate isolation of MSCs from the umbilical cord matrix tissue and assess their safety and efficacy to improve Parkinsonian symptoms in an in vivo animal model. The efficacy of MSCs from BM and umbilical cord in the PD animal mode has also been studied, and more importantly the efficacy of using differentiated UCMSC (D‐UCMSCs) to dopaminergic phenotype. Phenotypically, UCMSCs expressed higher levels of SSEA4 compared to BMMSCs. Analysis of differentiated cells showed that D‐UCMSCs expressed significant levels of Tyrosine Hydroxyalse and Nurr1 compared to D‐BMMSCs. The in vivo efficacy of the differentiated and undifferentiated cell types in the Parkinsonian rats showed that D‐UCMSCs improved the symptoms throughout a year of study. Differentiated cell types are potentially better for clinical use than the undifferentiated type, provided they are made available at the site of action in adequate numbers. MSCs are less immunogenic and immunomodulatory, which opens up the further possibility of using these cells in allogeneic settings. This could be a novel cell therapy application, especially when getting autochthonous cells is difficult.

Topics

No keywords indexed for this article. Browse by subject →

References

39

[1]

10.1182/blood-2004-04-1559

[2]

10.1002/eji.200425405

[3]

10.1111/j.1582-4934.2004.tb00320.x

[4]

10.1371/journal.pone.0005222

[5]

10.1089/scd.2006.15.141

[6]

10.1523/jneurosci.3314-07.2008

[7]

10.1016/j.brainres.2009.11.041

[8]

10.3109/14653249.2011.579957

[9]

10.1634/stemcells.2005-0370

[10]

10.1634/stemcells.2005-0053

[11]

10.1586/ern.11.74

[12]

Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: A comparative study in two mouse strains

Reena Haobam, Kizhakke M. Sindhu, Goutam Chandra et al.

Behavioural Brain Research 10.1016/j.bbr.2005.04.011

[13]

10.1016/j.neulet.2005.10.097

[14]

10.1080/14653240802021330

[15]

10.1007/s11064-010-0211-6

[16]

10.1182/blood-2003-11-3909

[17]

10.1634/stemcells.21-1-50

[18]

10.1016/s0960-9822(00)00033-6

[19]

10.1002/jnr.20147

[20]

Nikenejad H "Differentiation factors that influence neuronal markers expression in vitro from human amniotic epithelial cells" Eur Cells Mater (2010) 10.22203/ecm.v019a03

[21]

10.1016/j.bbrc.2008.06.022

[22]

Rocky ST "Adult mesenchymal stem cells and cell‐based tissue engineering" Arthritis Res Ther (2002)

[23]

10.1634/stemcells.2004-0166

[24]

10.1038/cr.2008.80

[25]

10.1016/j.cellbi.2009.05.002

[26]

10.4103/0973-6247.59386

[27]

10.1080/08860220902928981

[28]

10.1016/j.brainres.2006.05.109

[29]

10.1634/stemcells.2008-0963

[30]

10.1016/j.bone.2006.09.013

[31]

10.15283/ijsc.2010.3.2.103

[32]

10.1038/icb.2010.47

[33]

10.1111/j.1432-0436.2004.07207003.x

[34]

10.1634/stemcells.2007-0212

[35]

10.1634/stemcells.2005-0330

[36]

10.1634/stemcells.2007-1028

[37]

Woodbury D "Adult bone marrow stromal cells express germline, ectodermal, endodermal and mesodermal genes prior to neurogenesis" J Neurosci Res (2002)

[38]

10.1038/gt.2010.152

[39]

10.1016/j.brainres.2006.12.061

Cited By

35

Allogeneic umbilical cord-derived mesenchymal stem cell transplantation for treating chronic obstructive pulmonary disease: a pilot clinical study

Phuong Le Thi Bich, Ha Nguyen Thi · 2020

Stem Cell Research & Therapy

Metrics

35

Citations

39

References

Details

Published: Jan 21, 2013
Vol/Issue: 37(2)
Pages: 167-180
License: View

Authors

P

Prathibha Shetty

Regenerative Medicine Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life Sciences Centre R‐282, TTC Industrial Area of MIDC Thane Belapur Road, Rabale, Navi, Mumbai 400701 India

A

Anirban M. Thakur

Laboratory Animal Research Services Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life Sciences Centre R‐282, TTC Industrial Area of MIDC Thane Belapur Road, Rabale, Navi, Mumbai 400701 India

C

Chandra Viswanathan

Regenerative Medicine Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life Sciences Centre R‐282, TTC Industrial Area of MIDC Thane Belapur Road, Rabale, Navi, Mumbai 400701 India

Cite This Article

Prathibha Shetty, Anirban M. Thakur, Chandra Viswanathan (2013). Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model. Cell Biology International, 37(2), 167-180. https://doi.org/10.1002/cbin.10029

Dopaminergic cells, derived from a high efficiency differentiation protocol from umbilical cord derived mesenchymal stem cells, alleviate symptoms in a Parkinson's disease rodent model

You May Also Like